

**Oklahoma Health Care Authority**  
**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – January 9, 2013 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. December 12, 2012 DUR Minutes – Vote
  - B. December 13, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Medication Coverage Activity for December 2012
  - B. Pharmacy Help Desk Activity for December 2012
  - C. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Linzess™ and Update Amitiza® Criteria – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

6. **60 Day Notice to Prior Authorize Chronic Obstructive Pulmonary Disease Medications – See Appendix D.**
  - A. Utilization Review
  - B. Cost Comparison
  - C. Economic Impact
  - D. Market Analysis
  - E. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Antihyperlipidemics and 30 Day Notice to Prior Authorize Vascepa™ and Juxtapid™ – See Appendix E.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Update
  - E. Vascepa™ and Juxtapid™ Product Summaries
  - F. COP Recommendations
  - G. Utilization Details
  - H. Vascepa™ and Juxtapid™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Osteoporosis Medications and 30 Day Notice to Prior Authorize Binosto™ See Appendix F.**
- A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Market News and Update
  - E. COP Recommendations
  - F. Utilization Details
  - G. Binosto™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Xeljanz® – See Appendix G.**
- A. Summary
  - B. Mechanism of Action
  - C. Efficacy
  - D. Safety
  - E. Cost
  - F. COP Recommendations
  - G. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**
11. **Future Business**
- A. DUR of Oral Corticosteroids
  - B. Annual Reviews
  - C. New Product Reviews
12. **Adjournment**